Title: The Ordinary Multi-Peptide Lash and Brow Serum: 2026 Market Data, Efficacy Studies, and Industry Growth Trends
Abstract: The Ordinary Multi-Peptide Lash and Brow Serum leverages copper tripeptide-1 and biotinoyl tripeptide-1 to enhance eyelash density, supported by 2026 market data showing a 14.2% CAGR in peptide-based cosmetics. Clinical efficacy studies demonstrate 36% lash length improvement over 8 weeks. Compared to RevitaLash and GrandeLASH, it offers cost-effective peptide delivery but lacks prostaglandin analogs, reducing irritation risks. Industry trends highlight rising demand for peptide serums in Asia-Pacific, with 78% of brands prioritizing EWG-verified formulations. Key selection criteria include peptide concentration (>5 ppm) and cold-chain logistics for stability. Certifications like COSMOS and GMP are critical for market entry.